argenx
argenx works on 12 rare diseases tracked on Trial Friend, including Chronic Inflammatory Demyelinating Polyneuropathy, Dermatomyositis, Epidermolysis Bullosa and 9 more, with 27 active clinical trials (21 recruiting) and 2 FDA-approved rare disease drugs.
argenx is a global immunology company focused on FcRn-blocking antibody therapies for rare autoimmune diseases. Vyvgart (efgartigimod alfa), given by IV infusion, was approved in December 2021 for adults with generalized myasthenia gravis who test positive for AChR antibodies. Vyvgart Hytrulo, given as an injection under the skin, was approved for the same group in June 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in June 2024, and a prefilled syringe for self-injection followed in April 2025. On May 8, 2026, the FDA expanded both labels to all adults with generalized myasthenia gravis, including people who test positive for MuSK or LRP4 antibodies and people who test negative for AChR, MuSK and LRP4 antibodies. In August 2026, argenx and Zai Lab reported that the Phase 3 ALKIVIA trial met its main goal in autoimmune myositis. Registrational trials continue in immune thrombocytopenia, Sjögren's disease and Graves' disease, and empasiprubart is in registrational trials for multifocal motor neuropathy and CIDP. argenx stopped its pemphigus program after the Phase 3 ADDRESS trial missed its main goal in December 2023.
argenx Drug Pipeline
argenx has 27 active clinical trials across 4 development stages, with 21 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline counts the active and recruiting trials listed on this page, from ClinicalTrials.gov. For companies that work outside rare disease, we list only trials for rare diseases we track, so the company's full pipeline may be larger.
argenx Clinical Trials (27)
Active and recruiting clinical trials sponsored by argenx, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only argenx. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Chronic Inflammatory Demyelinating Polyneuropathy. Turn any of these off from the link in every email.
argenx FDA-Approved Drugs (2)
Medications developed or marketed by argenx that have received U.S. Food and Drug Administration approval. Drug data is sourced from the openFDA database and includes brand names, generic names, approval dates, and matched rare disease indications. Where a drug treats a condition covered by Trial Friend, the disease name links directly to that disease page.
| Drug Name | Brand Name | Rare Diseases | Approval Date |
|---|---|---|---|
| EFGARTIGIMOD ALFA Neonatal Fc Receptor Blocker [EPC] | VYVGART intravenous | Dec 17, 2021 | |
| EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT) Neonatal Fc Receptor Blocker [EPC] | VYVGART Hytrulo subcutaneous | Jun 20, 2023 |
argenx Trial Locations
argenx clinical trials are running at 1,514 sites in 59 countries. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (12)
Diseases targeted by argenx's clinical trial and drug development programs
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an autoimmune disorder affecting the peripheral nerves, causing progressive weakness and impaired function in the legs and arms. The immune ...
Dermatomyositis is a rare autoimmune inflammatory disease causing muscle weakness and distinctive skin rashes, particularly over joints. It involves inflammation of muscles and skin blood vessels. Abo...
Epidermolysis bullosa is a group of rare genetic blistering disorders caused by mutations affecting proteins anchoring the epidermis to the dermis. Fragile skin blisters and erodes with minimal trauma...
Graves' disease is the most common cause of hyperthyroidism, an autoimmune condition where antibodies stimulate the thyroid gland to produce excessive thyroid hormone. It can cause a wide range of sym...
Guillain-Barré syndrome is a rare autoimmune neurological disorder in which the body's immune system attacks the peripheral nerves, causing rapidly progressive muscle weakness that typically starts in...
IgA nephropathy is the most common primary glomerulonephritis worldwide, caused by abnormal IgA1 antibodies depositing in the kidney's mesangium, activating complement pathways and triggering inflamma...
Patient Resources
Organizations and resources related to argenx's rare disease focus areas
Frequently Asked Questions About argenx
Common questions about argenx's rare disease programs, clinical trials, and treatments.